|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Migraine - Lots of Experience, But Less Expertise
Datamonitor, Jan 2004, Pages: 113
Introduction
Headache is the most common complaint seen in family practice in the US, yet medical training gives little time to its diagnosis and treatment. Enabling improved diagnosis and an understanding of suitable treatment pathways for migraine will allow pharmaceutical companies to more suitably position and differentiate their product.
Scope
A review of diagnosis and classification of migraine including epidemiology in the seven major markets
Analysis of therapeutic classes- triptans, ergotamines and alternative treatment options. Including product profiles of key drugs within each class
An assessment of drug delivery options
Highlights
The triptan market is highly crowded, with a perception of little to offer between available treatments. Clear needs are identified, but research shows that these are either not, or incompletely met.
As with many disorders, novel formulations and delivery systems can provide a product with a differentiator to maintain/improve its status in the market. In addition to this, such devices for migraine can help build key attributes to meet the needs in specific migraine segments.
Long-term prophylactic management of migraine offers significant commercial opportunity. Such an indication has generally been seen as an add-on, without due consideration given to an assessment of the unique needs of this area
Reasons to Purchase
Benchmark pipeline migraine treatments and currently marketed products and assess future market potential
Understand how physicians position current therapies
Identify potential marketing opportunities both with prescribers and consumers
Region: US
Customers who bought this item also bought
Commercial Insight: Migraine - A Painful Future for the Triptans?
Market Dynamics 2000: Migraine - Dominance of Triptans in the Global Market
Commercial Insight: Migraine - Opportunities will Exist in the Wake of Generic Attack
Drugs of Tomorrow 2001: Migraine - Impact of the Novel Triptan Class on Acute Treatment Market
Disease and Therapy Review: Migraine
Menstrual Migraine - An opportunity to gain a competitive advantage for triptan manufacturers
Outlook for the Migraine Market With Novel Approaches Limited, Triptans Dominate
Migraine: positioning triptans in an increasingly competitive market
Forecast Insight: Migraine - Generic Incursion Inhibits Market Growth
Pipeline Insight: Migraine - Innovation Essential as Weak Late-stage Pipeline Fails to Hold off the Impact of Triptan Patent Expiries
Treatment Algorithms 2002: Venous Thromboembolism Acute Therapy
Treatment Algorithms 2001: Schizophrenia - The Rise of Atypical Neuroleptics as the Physicians’ Favorite
|
|
|
|
